Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

被引:15
|
作者
Lee, Dae Hyun [1 ,2 ]
Kumar, Abhishek [3 ]
Mohammed, Turab [4 ,5 ]
Peres, Lauren C. [6 ]
Alsina, Melissa [5 ]
Bachmeier, Christina
Blue, Brandon J. [5 ]
Brayer, Jason
Chandrasekhar, Sanjay [2 ]
Cruz, Ariel Grajales [5 ]
De Avila, Gabe
Elmariah, Hany [4 ]
Faramand, Rawan [4 ]
Freeman, Ciara [4 ]
Jain, Michael [4 ]
Khadka, Sushmita [4 ]
Khimani, Farhad [4 ]
Liu, Hien [4 ]
Nishihori, Taiga [4 ]
Oswald, Laura B. [1 ,7 ]
Puglianini, Omar A. Castaneda [4 ]
Shain, Kenneth H. [5 ]
Smith, Eric [4 ]
Baz, Rachid C. [5 ]
Locke, Frederick L. [4 ]
Oliveira, Guilherme H. [1 ,2 ]
Alomar, Mohammed [1 ,2 ]
Hansen, Doris K. [4 ]
机构
[1] Univ South Florida Morsani, Coll Med, Div Cardiovasc Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Cardiooncol, Tampa, FL USA
[3] Univ South Florida Morsani, Dept Internal Med, Coll Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunoth, Tampa, FL 33612 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
关键词
T-CELL THERAPY; CARDIOVASCULAR EVENTS; ADULTS;
D O I
10.1182/bloodadvances.2023009766
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, & lambda; light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (& GE;grade 2) cytokine release syndrome (CRS) and immune cell-associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.
引用
收藏
页码:4247 / 4257
页数:11
相关论文
共 50 条
  • [21] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
  • [22] Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel
    Paul, Barry
    Robinson, Myra
    Symanowski, James
    Foureau, David M.
    Norek, Sarah
    Bhutani, Manisha
    Ferreri, Christopher
    Ndiaye, Ami P.
    Robinson, Jordan
    Atrash, Shebli
    Varga, Cindy
    Friend, Reed
    Pineda-Roman, Mauricio
    Smith, April
    Duda, Jessica
    Cooper, Lance
    Kitali, Amani
    Voorhees, Peter M.
    BLOOD, 2024, 144 : 7027 - 7028
  • [23] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
    Mancuso, Katia
    Barbato, Simona
    Talarico, Marco
    Tacchetti, Paola
    Zamagni, Elena
    Cavo, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
  • [24] Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study
    Chang, Darryl
    Habib, Alma
    Uegel, Andrew
    Struble, Emily
    Shaikh, Hira
    Strouse, Christopher
    Green, Kimberly M.
    Mushtaq, Muhammad Umair
    Mahmoudjafari, Zahra
    Hashmi, Hamza
    Mcguirk, Joseph P.
    Khan, Abdullah Mohammad
    Abdallah, Al-Ola
    Ahmed, Nausheen
    Atrash, Shebli
    Bhutani, Manisha
    BLOOD, 2024, 144 : 2404 - 2405
  • [25] KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
    Sundar Jagannath
    Yi Lin
    Hartmut Goldschmidt
    Donna Reece
    Ajay Nooka
    Alicia Senin
    Paula Rodriguez-Otero
    Ray Powles
    Kosei Matsue
    Nina Shah
    Larry D. Anderson
    Matthew Streetly
    Kimberly Wilson
    Hoa Van Le
    Arlene S. Swern
    Amit Agarwal
    David S. Siegel
    Blood Cancer Journal, 11
  • [26] KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
    Jagannath, Sundar
    Lin, Yi
    Goldschmidt, Hartmut
    Reece, Donna
    Nooka, Ajay
    Senin, Alicia
    Rodriguez-Otero, Paula
    Powles, Ray
    Matsue, Kosei
    Shah, Nina
    Anderson, Larry D., Jr.
    Streetly, Matthew
    Wilson, Kimberly
    Van Le, Hoa
    Swern, Arlene S.
    Agarwal, Amit
    Siegel, David S.
    BLOOD CANCER JOURNAL, 2021, 11 (06)
  • [27] RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
    Ricardo D. Parrondo
    Keren Sam
    Ahsan Rasheed
    Victoria Alegria
    Taimur Sher
    Vivek Roy
    Asher Chanan-Khan
    Sikander Ailawadhi
    Blood Cancer Journal, 12
  • [28] Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Imanak, Ken
    Lee, Abraham
    Campbell, Timothy B.
    Patwardhan, Pallavi
    ADVANCES IN THERAPY, 2023, 40 (10) : 4626 - 4638
  • [29] Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
    November McGarvey
    Brian Ung
    Thomas Carattini
    Ken Imanak
    Abraham Lee
    Timothy B. Campbell
    Pallavi Patwardhan
    Advances in Therapy, 2023, 40 : 4626 - 4638
  • [30] CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA
    Lee, Dae Hyun
    Chandrasekhar, Sanjay Amrith
    Jain, Michael
    Hansen, Doris
    Freeman, Ciara
    Alsina, Melissa
    Baz, Rachid
    Puglianini, Omar Castaneda
    Liu, Hien
    Blue, Brandon
    Davila, Marco L.
    Faramand, Rawan
    Kumar, Abhishek
    Shah, Bijal
    Lazaryan, Aleksandr
    Khimani, Farhad
    Nishihori, Taiga
    Bachmeier, Christina
    Locke, Frederick
    Oliveira, Guilherme Henrique
    Alomar, Mohammed
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1933 - 1933